PT-796

PT-796 is a **preclinical bispecific antibody** being developed by **Phanes Therapeutics** for oncology, with public drug-database sources describing it as a **CD47- and FOLR1-targeting antibody candidate** for **ovarian cancer**. Based on those sources, the program is intended to combine **CD47 blockade**, which can enhance macrophage-mediated antitumor phagocytosis by disrupting the CD47 \"don't eat me\" signal, with **FOLR1-directed tumor targeting** in folate receptor alpha-expressing ovarian tumors. Publicly accessible evidence is limited and I did not find a sponsor primary-source page or registered clinical trial directly naming PT-796, so the available characterization should be treated as provisional rather than fully sponsor-verified.